EC
BSX icon

Eleva Capital’s Boston Scientific BSX Stock Holding History

Eleva Capital’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-26,667
Closed -$1.67M – 29
2026
Q2 		$1.67M Hold
26,667
– – 0.49% 12
2026
Q1 		$1.67M Buy
+26,667
New +$2.13M 0.49% 12

Other funds holding BSX

NRS
Neville Rodie & Shaw New York $1.48B AUM 34.49% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return
BONH
Bank of New Hampshire Laconia, New Hampshire $463M AUM 23.57% 1-Year Est. Return
MHR
Matthew Hamilton Rosenberg $558M AUM 12.28% 1-Year Est. Return

Eleva Capital's BSX Position: Q3 2026 in Review

Eleva Capital sold out of Boston Scientific (BSX) in Q3 2026, closing a stake of 26,667 shares — an estimated $1.67M sold.

Eleva Capital first reported a position in BSX in Q1 2026 and held it in 2 quarters. The position peaked at $1.67M in Q2 2026. 16 funds tracked by Wall St. Rank hold BSX as of Q3 2026.

  • Eleva Capital reported no remaining Boston Scientific position as of Q3 2026 after selling out during the quarter.
  • Eleva Capital sold 26,667 Boston Scientific shares in Q3 2026, an estimated $1.67M.
  • Eleva Capital first reported a position in Boston Scientific in Q1 2026 and held it in 2 quarters.
  • Eleva Capital's Boston Scientific position peaked at $1.67M in Q2 2026.
  • 16 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2026.

Based on Eleva Capital's 13F filing for Q3 2026, filed 6 Oct 2026.